Efficacy and Safety of Intravenous HRS8179 on Brain Swelling After Large Hemispheric Infarction: a Randomised, Double-blind, Placebo-controlled Phase II Trial
Latest Information Update: 08 Jan 2025
At a glance
- Drugs HRS 8179 (Primary)
- Indications Brain oedema
- Focus Therapeutic Use
- Sponsors Beijing Suncadia Pharmaceuticals
- 06 Jan 2025 Status changed from active, no longer recruiting to completed.
- 09 May 2024 Planned End Date changed from 15 Jan 2024 to 1 Dec 2024.
- 09 May 2024 Status changed from not yet recruiting to active, no longer recruiting.